Myriad Genetics (MYGN) Inventory (2011 - 2026)

Myriad Genetics (MYGN) has 16 years of Inventory data on file, last reported at $27.9 million in Q1 2026.

• Inventory for Q1 2026 came in at $27.9 million, down 1.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.9 million (down 1.41% YoY), and the FY2025 annual result was $30.6 million, up 11.27% from the prior year.
• Inventory retreated to $27.9 million in Q1 2026 per MYGN's latest filing, from $30.6 million in the prior quarter.
• Over five years, Inventory peaked at $31.6 million in Q3 2025 and troughed at $15.4 million in Q2 2022.
• A 5-year average of $24.3 million and a median of $25.1 million in 2023 frame the typical range for Inventory.
• The sharpest annual moves came in 2022 and 2023: Inventory tumbled 36.59% in 2022, then soared 46.1% in 2023.
• A 5-year view of Inventory shows it stood at $20.1 million in 2022, then advanced by 9.45% to $22.0 million in 2023, then advanced by 25.0% to $27.5 million in 2024, then advanced by 11.27% to $30.6 million in 2025, then declined by 8.82% to $27.9 million in 2026.
• Business Quant data shows MYGN's Inventory at $27.9 million in Q1 2026, $30.6 million in Q4 2025, and $31.6 million in Q3 2025.